Inventors list |
Assignees list |
Classification tree browser |
Top 100 Inventors |
Top 100 Assignees |
Burns, AU
Alan Robert Burns, Dalkeith AU
| Patent application number | Description | Published |
|---|---|---|
| 20100314014 | TYRE | 12-16-2010 |
Alan Robert Burns, Western Australia AU
| Patent application number | Description | Published |
|---|---|---|
| 20090107328 | Reciprocating Pump - A reciprocating pump ( | 04-30-2009 |
| 20100171312 | BUOYANT ACTUATOR - A buoyant actuator ( | 07-08-2010 |
| 20100219065 | WAVE ENGERGY CONVERSION - Apparatus ( | 09-02-2010 |
Alexander Jeffrey Burns, Willetton AU
| Patent application number | Description | Published |
|---|---|---|
| 20090301720 | REMOTE PLUGGING DEVICE FOR WELLS - Remote cement plugging device ( | 12-10-2009 |
Christopher John Burns, Victoria AU
| Patent application number | Description | Published |
|---|---|---|
| 20080207613 | Selective Kinase Inhibitors - A compound of the general formula (I) or pharmaceutically acceptable prodrugs, salts, hydrates, solvates, crystal forms or diastereomers thereof, wherein A represents a variety of six membered nitrogen containing heterocyclic rings, Q is a bond, halogen, C | 08-28-2008 |
Christopher John Burns, Melbourne AU
| Patent application number | Description | Published |
|---|---|---|
| 20110092499 | N-CONTAINING HETEROCYCLIC COMPOUNDS - The present invention relates to N-containing heterocyclic compounds that are inhibitors of protein kinases including JAK kinases. In particular, the compounds are selective for JAK1, JAK2, JAK3 or TYK2 kinases and combinations thereof such as JAK1 and JAK2. The kinase inhibitors can be used in the treatment of kinase associated diseases such as immunological and inflammatory diseases including organ transplants; hyperproliferative diseases including cancer and myeloproliferative diseases; viral diseases; metabolic diseases; and vascular diseases. | 04-21-2011 |
Christopher John Burns, Seddon AU
| Patent application number | Description | Published |
|---|---|---|
| 20110269760 | TUBULIN INHIBITORS - Compounds of general formula (I), (II), (III) and (V) are described for use in modulating microtubule polymerisation and in the treatment of associated disease states. Use of compounds (I), (III) and (V) in the treatment of kinase-associated disease states is also described. Further described are novel compounds of formula (II), (III) and (V). | 11-03-2011 |
Christopher John Burns, Richmond AU
| Patent application number | Description | Published |
|---|---|---|
| 20100130447 | INHIBITORS OF KINASE ACTIVITY - The present invention relates to pyridines or pyrazines that inhibit kinases. In particular the compounds of the invention inhibit members of the class III PTK receptor family such as FMS (CSF-IR), c-KIT, PDGFRβ, PDGFRα or FLT3 and KDR, SRC, EphA2, EphA3, EphA8, FLT1, FLT4, HCK, LCK, PTK5 (FRK), SYK, DDR1 and DDR2 and RET. The compounds of the invention are useful in the treatment of kinase associated diseases such as immunological and inflammatory diseases; hyperproliferative diseases including cancer and diseases involving neo-angiogenesis; renal and kidney diseases; bone remodeling diseases; metabolic diseases; and vascular diseases. | 05-27-2010 |
| 20100197671 | PHENYL AMINO PYRIMIDINE COMPOUNDS AND USES THEREOF - The present invention relates to phenyl amino pyrimidine compounds which are inhibitors of protein kinases including JAK kinases. In particular the compounds are selective for JAK2 kinases. The kinase inhibitors can be used in the treatment of kinase associated diseases such as immunological and inflammatory diseases including organ transplants; hyperproliferative diseases including cancer and myeloproliferative diseases; viral diseases; metabolic diseases; and vascular diseases. | 08-05-2010 |
| 20100239631 | THIOPYRIMIDINE-BASED COMPOUNDS AND USES THEREOF - The present invention relates to thiopyrimidine-based compounds that are inhibitors of protein kinases including JAK kinases. In particular, the compounds are selective for JAK1, JAK2 or JAK3 kinases and combinations thereof such as JAK1 and JAK2. The kinase inhibitors can be used in the treatment of kinase associated diseases such as immunological and inflammatory diseases including organ transplants; hyperproliferative diseases including cancer and myeloproliferative diseases; viral diseases; metabolic diseases and vascular diseases. | 09-23-2010 |
| 20110082142 | SELECTIVE KINASE INHIBITORS - A compound of the general formula (I) or pharmaceutically acceptable prodrugs, salts, hydrates, solvates, crystal forms or diastereomers thereof, wherein A represents a variety of six membered nitrogen containing heterocyclic rings, Q is a bond, halogen, C | 04-07-2011 |
Christopher John Burns, North Caulfield AU
| Patent application number | Description | Published |
|---|---|---|
| 20090281119 | ACID ADDITION SALTS OF N-ETHYI-N'-[2-METHOXY-4-(5-METHYI-4-PRYIMIDIN-2-YL)PHENYL]UREA AND USES THEREOF - The present invention provides an acid addition salt of N-ethyl-N′-[2-methoxy-4-(5-methyl-4-{[(1S)-1-pyridin-3-ylbutyl]amino}pyrimidin-2-yl)phenyl]urea and uses thereof including a method for the treatment of a hyperproliferation-related disorder. The present invention also provides a pharmaceutical composition comprising an acid addition salt of N-ethyl-N′-[2-methoxy-4-(5-methyl-4-{[(1S)-1-pyridin-3-ylbutyl]amino}pyrimidin-2-yl)phenyl]urea. | 11-12-2009 |